Everything below concerns anti-doping. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
In February 2022, journalist Marwan Bishara held the US and Russia responsible for pursuing "their own narrow interests", including then-US president Trump's recognition of Jerusalem as capital of Israel as well as Putin's Russian invasion of Ukraine, and for "pav[ing] the way for, well, another Cold War".
In the United States, dog foods labelled as "complete and balanced" must meet standards established by the Association of American Feed Control Officials (AAFCO), either by meeting a nutrient profile or by passing a feeding trial. The Dog Food Nutrient Profiles were last updated in 2016 by the AAFCO's Canine Nutrition Expert Subcommittee. Critics argue that due to the limitations of the trial and the gaps in knowledge within animal nutrition science, the term "complete and balanced" is inaccurate and even deceptive. An AAFCO panel expert has stated that "although the AAFCO profiles are better than nothing, they provide false securities." Certain manufacturers label their products with terms such as "premium", "ultra premium", "natural", and "holistic". Such terms currently have no legal definitions and are not regulated. There are also varieties of dog food labeled as "human-grade food." Although no official definition of this term exists, the assumption is that other brands use foods that would not pass US Food and Drug Administration inspection according to the Pure Food and Drug Act or the Meat Inspection Act. The ingredients on the label must be listed in descending order by weight before cooking. This means before all of the moisture is removed from the meat, fruits, vegetables and other ingredients used.
== Absorption, metabolism and excretion == As part of the digestive process, food-sourced carotenoids must be separated from plant cells and incorporated into lipid-containing micelles to be bioaccessible to intestinal enterocytes. If already extracted (or synthetic) and then presented in an oil-filled dietary supplement capsule, there is greater bioavailability compared to that from foods. At the enterocyte cell wall, β-carotene is taken up by the membrane transporter protein scavenger receptor class B, type 1 (SCARB1). Absorbed β-carotene is then either incorporated as such into chylomicrons or first converted to retinal and then retinol, bound to retinol binding protein 2, before being incorporated into chylomicrons. The conversion process consists of one molecule of β-carotene cleaved by the enzyme beta-carotene 15,15'-dioxygenase, which is encoded by the BCO1 gene, into two molecules of retinal. When plasma retinol is in the normal range the gene expression for SCARB1 and BCO1 are suppressed, creating a feedback loop that suppresses β-carotene absorption and conversion. The majority of chylomicrons are taken up by the liver, then secreted into the blood repackaged into low density lipoproteins (LDLs). From these circulating lipoproteins and the chylomicrons that bypassed the liver, β-carotene is taken into cells via receptor SCARB1. Human tissues differ in expression of SCARB1, and hence β-carotene content. Examples expressed as ng/g, wet weight: liver=479, lung=226, prostate=163 and skin=26.
Sources: en.wikipedia.org
== Clinical significance == A mutation in the tyrosinase gene resulting in impaired tyrosinase production leads to type I oculocutaneous albinism, a hereditary disorder that affects one in every 20,000 people. Tyrosinase activity is very important. If uncontrolled during the synthesis of melanin, it results in increased melanin synthesis. Decreasing tyrosinase activity has been targeted for the improvement or prevention of conditions related to the hyperpigmentation of the skin, such as melasma and age spots. Several polyphenols, including flavonoids or stilbenoid, substrate analogues, free radical scavengers, and copper chelators, have been known to inhibit tyrosinase. Henceforth, the medical and cosmetic industries are focusing research on tyrosinase inhibitors to treat skin disorders.
A tea made of the leaves and stem has been used to treat tooth pain. For cases of cough and bronchitis, a water extract (decoction) of Mimosa tenuiflora is drunk. A handful of bark in one liter of water is used by itself or in a syrup. The solution is drunk until the symptoms subside. One preliminary clinical study found Mimosa tenuiflora to be effective in treating venous leg ulcerations. Aqueous extracts of Mimosa are widely used for wound healing and burns in Central and South America. Consequently, the products of the plant (generally grouped under the term "Tepezcohuite") have become a popular and easily produced cosmetic ingredient in commercial skincare products.
=== Fetal blood supply === In the growing fetus, a major source of blood to the liver is the umbilical vein, which supplies nutrients to the growing fetus. The umbilical vein enters the abdomen at the umbilicus and passes upward along the free margin of the falciform ligament of the liver to the inferior surface of the liver. There, it joins with the left branch of the portal vein. The ductus venosus carries blood from the left portal vein to the left hepatic vein and then to the inferior vena cava, allowing placental blood to bypass the liver. In the fetus, the liver does not perform the normal digestive processes and filtration of the infant liver because nutrients are received directly from the mother via the placenta. The fetal liver releases some blood stem cells that migrate to the fetal thymus, creating the T cells (or T lymphocytes). After birth, the formation of blood stem cells shifts to the red bone marrow. After 2–5 days, the umbilical vein and ductus venosus are obliterated; the former becomes the round ligament of liver and the latter becomes the ligamentum venosum. In the disorders of cirrhosis and portal hypertension, the umbilical vein can open up again. Unlike eutherian mammals, in marsupials the liver remains haematopoietic well after birth.
osmosis The spontaneous net movement or diffusion of molecules of a solvent (e.g. water) through a selectively permeable membrane separating two solutions with different concentrations of dissolved solutes, in the direction that tends to equalize the solute concentrations on the two sides, i.e. from the more dilute solution to the more concentrated solution, or, equivalently, from a region of high water potential to a region of low water potential. Because the solute is unable to cross the membrane, the tendency towards equilibration compels the solvent to cross the membrane instead. This continues until an equilibrium is reached, where neither side of the membrane is more or less concentrated than the other.
Sources: en.wikipedia.org
If, in addition, the rate of photoionization is greater than the rate of consumption of intermediates, then each selected state is converted to one electron plus one positive ion, so that the RIS process is saturated. A usually efficient way to produce free atoms of an element in the ground state is to atomize the elements by ion sputtering or thermal vaporization of the element from a laser matrix under vacuum conditions or at environments with pressures significantly less than normal atmospheric pressure. The resulting plume of secondary atoms is then channeled through the path of multiple tuned laser beams which are capable of exciting consecutive electronic transitions in the specified element. Light from these tuned lasers promotes the desired atoms above their ionization potentials whereas interfering atoms from other elements are hardly ionized since they are generally transparent to the laser beam. This process produces photoions which are extracted and directed towards an analytical facility such as a magnetic sector to be counted. This approach is extremely sensitive to atoms of the specified element so that the ionization efficiency is almost 100% and also elementally selective, due to the highly unlikely chance that other species will be resonantly ionized. To achieve high ionization efficiencies, monochromatic lasers with high instantaneous spectral power are used. Typical lasers being used include continuous-wave lasers with extremely high spectral purity and pulsed lasers for analyses involving limited atoms.
characterizes the potential for initial spread of an infectious person in a naive population, assuming the change in the susceptible population is negligible during the initial spread. A linear system of ODEs can always be described by a matrix. So, the next step is to construct a linear positive operator that provides the next generation of infected people when applied to the present generation. Note that this operator (matrix) is responsible for the number of infected people, not all the compartments. Iteration of this operator describes the initial progression of infection within the heterogeneous population. So comparing the spectral radius of this operator to unity determines whether the generations of infected people grow or not.
== Controversy == In 2020, Horsley was involved in a Twitter feud. In 2021, Horsley had a dispute with fellow Hamden councilmember Justin Farmer, when she asked that he address her as "doctor", which was requested by the Hamden Council President a few months earlier in solidarity with Jill Biden. Her resignation was requested but Horsley finished her term. Despite this political opposition, Horsley has actively supported diversity in science as a founding co-Chair of Society of Investigative Dermatology's Diversity Committee.
Aflatoxin B1 and B2 (AFB), produced by A. flavus and A. parasiticus Aflatoxin G1 and G2 (AFG), produced by some Group II A. flavus and Aspergillus parasiticus Aflatoxin M1 (AFM1), metabolite of aflatoxin B1 in humans and animals (exposure in ng levels may come from a mother's milk) Aflatoxin M2, metabolite of aflatoxin B2 in milk of cattle fed on contaminated foods Aflatoxicol (AFL): metabolite produced by breaking down the lactone ring Aflatoxin Q1 (AFQ1), major metabolite of AFB1 in in vitro liver preparations of other higher vertebrates AFM, AFQ, and AFL retain the possibility of becoming an epoxide. Nevertheless, they appear much less capable of causing mutagenesis than the unmetabolized ABM.
Kidney dialysis is the process of removing excess water, solutes, and toxins from the blood in people whose kidneys can no longer perform these functions naturally. Along with kidney transplantation, it is a type of renal replacement therapy. Dialysis may need to be initiated when there is a sudden rapid loss of kidney function, known as acute kidney injury (previously called acute renal failure), or when a gradual decline in kidney function, chronic kidney failure, reaches stage 5. Stage 5 chronic renal failure is reached when the glomerular filtration rate is less than 15% of the normal, creatinine clearance is less than 10 mL per minute, and uremia is present. Dialysis is used as a temporary measure in cases of acute kidney injury or for those awaiting kidney transplant and as a permanent measure in those for whom a transplant is not indicated or not possible. In West European countries, Australia, Canada, the United Kingdom, and the United States, dialysis is paid for by the government for those who are eligible. The first successful dialysis was performed in 1943.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.